Creative Planning Grows Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Creative Planning boosted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 4.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 42,815 shares of the company’s stock after purchasing an additional 1,863 shares during the period. Creative Planning’s holdings in Teva Pharmaceutical Industries were worth $772,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of TEVA. Maple Rock Capital Partners Inc. lifted its position in Teva Pharmaceutical Industries by 68.3% during the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock valued at $61,568,000 after purchasing an additional 1,770,000 shares in the last quarter. Iron Triangle Partners LP raised its holdings in Teva Pharmaceutical Industries by 113.1% during the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after acquiring an additional 1,469,864 shares during the period. Driehaus Capital Management LLC bought a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $23,115,000. Davidson Kempner Capital Management LP raised its holdings in Teva Pharmaceutical Industries by 152.5% during the second quarter. Davidson Kempner Capital Management LP now owns 1,765,485 shares of the company’s stock valued at $28,689,000 after acquiring an additional 1,066,150 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Teva Pharmaceutical Industries by 13.4% during the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after acquiring an additional 1,031,400 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Up 0.1 %

Shares of TEVA stock opened at $18.45 on Friday. Teva Pharmaceutical Industries Limited has a 12-month low of $8.55 and a 12-month high of $19.08. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. The stock’s 50-day moving average price is $18.02 and its 200-day moving average price is $16.95. The stock has a market capitalization of $20.90 billion, a price-to-earnings ratio of -47.31, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The company had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $3.99 billion. Equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Barclays raised their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Wednesday, July 10th. Finally, UBS Group raised their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.